ReviewNutrients2026
Natural Products in the Metabolic and Endocrine Modulation of Polycystic Ovary Syndrome: Current Perspectives.
Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Metabolic and Anti-Inflammatory Effects of Berberine-Rationale for Its Therapeutic Potential in Polycystic Ovary Syndrome.International journal of molecular sciences · 2026Review
- Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies.Medicina (Kaunas, Lithuania) · 2026Review
- Natural Products in Prostate Cancer: Crosstalk Among the Gut Microbiome, Androgen Receptor Signaling, and Epigenetic Regulation.International journal of molecular sciences · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder, primarily characterized by reproductive dysfunction, insulin resistance (IR), and long-term metabolic complications. Current first-line pharmacological treatments, including oral contraceptives, anti-androgens, and insulin sensitizers, can alleviate clinical symptoms but often fail to fully address the underlying pathophysiology, and their long-term use is frequently limited by adverse effects. Natural products, owing to their multi-target regulatory properties and favorable safety profiles, have emerged a promising adjuvant therapeutic strategy. This review systematically summarizes how natural products exert beneficial effects through mechanisms such as improving metabolic homeostasis by enhancing insulin sensitivity and mitigating oxidative stress and chronic inflammation; restoring endocrine balance by modulating the hypothalamic-pituitary-gonadal axis to reduce hyperandrogenemia and promote ovulation; and utilizing emerging pathways including regulating gut microbiota homeostasis and epigenetic modifications as a novel avenue for PCOS drug development. Preclinical and clinical evidence collectively indicates that these agents hold significant translational potential to ameliorate metabolic disturbances and improve reproductive outcomes, providing a scientific foundation for future integrated intervention strategies in PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.